Université Pierre et Marie Curie-Paris6, CNRS, UMR 7211, France.
J Hepatol. 2010 Aug;53(2):230-7. doi: 10.1016/j.jhep.2010.03.009. Epub 2010 Apr 27.
BACKGROUND & AIMS: To analyze the care of HCV infection in HIV-HCV coinfected patients and its progression between 2004 and 2009.
Three hundred eighty HIV-HCV coinfected patients were prospectively included from November 22 to 29, 2004 (2004 survey), 416 patients from April 3 to 10, 2006 (2006 survey), and 419 patients from June 15 to 22, 2009 (2009 survey).
The rate of liver biopsy decreased (14% vs. 38% vs. 56%), while the use of non-invasive liver damage tests increased (47% vs. 24% vs. ND) in the 2009, 2006, and 2004 surveys, respectively. The rate of patients that had never been treated for HCV infection progressively decreased in the 2009, 2006, and 2004 surveys (37%, 42%, and 54%). The main reasons for HCV non-treatment changed as HCV treatment was deemed less questionable and the lack of liver biopsy became a very rare reason (6%, 18%, and 34%). Among patients treated for HCV infection, the rate of sustained virological response increased (49%, 29%, and 29%). The main factors independently associated with HCV treatment were a liver fibrosis score > or =F2 (odds ratio=3.5; 95% CI 2.1-5.7), a liver biopsy activity grade > or =A2 (2.7; 1.4-5.3), a CD4 cell count > or =350 ml (2.7; 1.6-4.4), European origin (2.1; 1.3-3.4), daily alcohol consumption<30 g (2.1; 1.2-3.8), and male gender (2.0; 1.2-3.3).
Compared to the 2004 and 2006 surveys, the 2009 coinfected patients had liver damage assessment more frequently, more patients had received HCV treatment and more patients had achieved a sustained virological response.
分析 2004 年至 2009 年间 HIV-HCV 合并感染患者 HCV 感染的治疗情况及其进展。
2004 年 11 月 22 日至 29 日(2004 年调查)前瞻性纳入 380 例 HIV-HCV 合并感染患者,2006 年 4 月 3 日至 10 日(2006 年调查)纳入 416 例患者,2009 年 6 月 15 日至 22 日(2009 年调查)纳入 419 例患者。
肝活检率逐渐降低(14%、38%、56%),而非侵入性肝损伤检测使用率逐渐增加(47%、24%、ND)。在 2009 年、2006 年和 2004 年的调查中,从未接受 HCV 感染治疗的患者比例逐渐降低(37%、42%、54%)。未进行 HCV 治疗的主要原因是 HCV 治疗的质疑减少,且缺乏肝活检成为一个非常罕见的原因(6%、18%、34%)。在接受 HCV 感染治疗的患者中,持续病毒学应答率逐渐增加(49%、29%、29%)。与 HCV 治疗独立相关的主要因素包括肝纤维化评分≥F2(比值比=3.5;95%置信区间 2.1-5.7)、肝活检活动度分级≥A2(2.7;1.4-5.3)、CD4 细胞计数≥350/ml(2.7;1.6-4.4)、欧洲血统(2.1;1.3-3.4)、每日酒精摄入量<30g(2.1;1.2-3.8)和男性(2.0;1.2-3.3)。
与 2004 年和 2006 年的调查相比,2009 年合并感染患者的肝损伤评估更为频繁,更多的患者接受了 HCV 治疗,更多的患者实现了持续病毒学应答。